1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,630 | 0,830 | 17:26 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.11. | Ideaya pushes ahead with Biocytogen bispecific ADC bet | 1 | FierceBiotech | ||
| 11.11. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise | 177 | Business Wire | IDEAYA has exercised the option for an exclusive worldwide license on Biocytogen's potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate (BsADC), BCG034 (IDE034)... ► Artikel lesen | |
| 11.11. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT IDEAYA'S NOMINATION OF DEVELOPMENT CANDIDATE IDE034, A POTENTIAL FIRST-IN-CLASS B7H3/PTK7 TOPO-I-PAYLOAD ... | 3 | HKEx | ||
| 25.09. | BIOCYTOGEN-B (02315): 2024 INTERIM REPORT | 1 | HKEx | ||
| BIOCYTOGEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 28.08. | BIOCYTOGEN-B (02315): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024 | - | HKEx | ||
| 16.08. | BIOCYTOGEN-B (02315): DATE OF BOARD MEETING | 1 | HKEx | ||
| 07.08. | BIOCYTOGEN-B (02315): ANNOUNCEMENT ON PRELIMINARY FINANCIAL DATA FOR THE SIX MONTHS ENDED JUNE 30, 2024 | 1 | HKEx | ||
| 31.07. | IDEAYA in license agreement with Biocytogen for antibody drug conjugate program | 1 | Seeking Alpha | ||
| 31.07. | Ideaya, eyeing drug combos, bags option on Biocytogen bispecific ADC in $400M deal | 2 | FierceBiotech | ||
| 31.07. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program | 282 | Business Wire | Biocytogen granted IDEAYA an option for an exclusive worldwide license for potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) program
B7H3/PTK7... ► Artikel lesen | |
| 31.07. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT ENTERS INTO OPTION AND LICENSE AGREEMENT WITH IDEAYA FOR POTENTIAL FIRST-IN-CLASS B7H3/PTK7 TOPO-I-PAYLOAD ... | 2 | HKEx | ||
| 16.07. | SOTIO partners with Biocytogen to expand ADC oncology pipeline | 2 | Pharmaceutical Technology | ||
| 16.07. | Sotio taps Biocytogen to create bispecific ADCs in $326M deal | 1 | FierceBiotech | ||
| 16.07. | SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline | 280 | Business Wire | Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen's proprietary RenLite platform Agreement will enable SOTIO to significantly broaden... ► Artikel lesen | |
| 16.07. | SOTIO Biotech: SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline | 261 | Business Wire | Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen's proprietary RenLite platform Agreement will enable SOTIO to significantly broaden... ► Artikel lesen | |
| 16.07. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT ENTERS INTO MULTI-TARGET ANTIBODY AGREEMENT WITH SOTIO | 2 | HKEx | ||
| 21.06. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen erhält US-Patent für seine gemeinsame Leichtketten-Mausplattform RenLite | 424 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) gab jetzt die Erteilung eines Patents durch das United States Patent and Trademark Office (USPTO) für die von Biocytogen... ► Artikel lesen | |
| 21.06. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Awarded U.S. Patent for RenLite Common Light Chain Mouse Platform | 288 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLitefully human common... ► Artikel lesen | |
| 21.06. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT BIOCYTOGEN SECURES U.S. PATENT FOR RENLITE COMMON LIGHT CHAIN MOUSE PLATFORM | 2 | HKEx | ||
| 28.05. | BIOCYTOGEN-B (02315): POLL RESULTS OF THE 2023 ANNUAL GENERAL MEETING HELD ON MAY 28, 2024 | - | HKEx |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 1,552 | -1,27 % | PTA-News: Medigene AG: Medigene präsentiert Daten zu innovativer IFN-Gamma-Biosensor-Technologie bei SITC 2024 | DJ PTA-News: Medigene AG: Medigene präsentiert Daten zu innovativer IFN-Gamma-Biosensor-Technologie bei SITC 2024
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried (pta/12.11.2024/13:00)... ► Artikel lesen | |
| BIOFRONTERA | 2,845 | +6,16 % | Biofrontera's listed shares fall as Q3 revenue misses estimates | ||
| CLINUVEL | 8,075 | -1,04 % | Injecting hope: Clinuvel eyes higher SCENESSE usage in Europe | ||
| EDITAS MEDICINE | 2,276 | -0,70 % | Editas Medicine, Inc.: Editas Medicine Announces Third Quarter 2024 Results and Business Updates | Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine's proprietary targeted LNP in a key step to developing a novel... ► Artikel lesen | |
| BLUEBIRD BIO | 0,284 | -0,18 % | bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance | SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September... ► Artikel lesen | |
| ASEP MEDICAL | 0,038 | +8,05 % | Asep Medical wird in landesweit ausgestrahlter Dokumentarreihe präsentiert | Asep wurde für eine spezielle Dokumentarreihe mit dem Titel "Empowered, Hosted by Meg Ryan"
ausgewählt, bei der Führungspersonen aus Wissenschaft, Technologie und Medizin im Blickpunkt stehen.
... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 2,370 | -1,46 % | Cardiff Oncology secures patent for cancer drug combo | ||
| CELLECTAR BIOSCIENCES | 1,460 | -1,35 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update | Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting and Exposition Raised approximately $19.4 million with potential to raise... ► Artikel lesen | |
| FRESH TRACKS THERAPEUTICS | 0,730 | 0,00 % | Fresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company | ||
| CLEAN HARBORS | 238,90 | +1,70 % | Peering Into Clean Harbors' Recent Short Interest | ||
| SPERO THERAPEUTICS | 1,150 | +0,52 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update | Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov.... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,240 | -1,64 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE AND PHARMALINK ENTER INTO STRATEGIC PARTNERSHIP FOR SUGEMALIMAB IN MIDDLE EAST AND NORTH AFRICA ... | ||
| MESOBLAST | 0,870 | -9,84 % | MESOBLAST LIMITED: Becoming a substantial holder | ||
| PROTALIX BIOTHERAPEUTICS | 1,520 | -4,67 % | Protalix Biotherapeutics Aktie: Erfolgsstrategie geht auf! | Das israelische Biotechnologieunternehmen Protalix BioTherapeutics verzeichnete im dritten Quartal 2024 einen unerwarteten Gewinn. Der Nettogewinn belief sich auf 3,24 Millionen Dollar oder 0,03 Dollar... ► Artikel lesen | |
| PIERIS PHARMACEUTICALS | 15,400 | 0,00 % | +105% dank Fusion: SD-Report-Aktie Pieris fliegt! | Raketenalarm für Käufer unseres "Bullenturbo"-Reports: Mit Pieris Pharmaceuticals (WKN: A12G4Q) schießt eine Empfehlung des Berichts nach einer starken Fusion über +100% nach oben. Reportkäufer konnten... ► Artikel lesen |
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,625 Euro und damit -0,79 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.
